A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Trial Profile

A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2018

At a glance

  • Drugs LY 3023414 (Primary) ; Abemaciclib; Cisplatin; Fulvestrant; Letrozole; Midazolam; Pemetrexed
  • Indications Advanced breast cancer; Cancer; Lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 May 2018 Planned End Date changed from 1 Oct 2020 to 1 Mar 2021.
    • 25 May 2018 Planned primary completion date changed from 1 May 2018 to 1 Mar 2019.
    • 10 May 2018 Planned primary completion date changed from 1 Aug 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top